CEL-SCI Corporation (CEL-SCI) - Form 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended September 30, 2010.
Business Overview: CEL-SCI is a biopharmaceutical company focused on developing immunotherapies. Its lead product, Multikine, is a combination immunotherapy for cancer (specifically advanced primary head and neck cancer) currently preparing for a global Phase III clinical trial. The company also holds LEAPS technology for treating H1N1 (swine flu) and rheumatoid arthritis (CEL-2000), though these remain in pre-clinical or early clinical stages. Additionally, CEL-SCI operates a "cold fill" manufacturing facility in Baltimore, MD, intended for Multikine production and potential third-party services.
Operational Status: The company has no commercial product sales and relies on financing activities to fund operations. It is an accelerated filer with approximately 42 employees as of November 30, 2010.
Key Financial Metrics
| Metric | Fiscal 2010 | Fiscal 2009 |
|---|---|---|
| Revenue | $153,300 | $80,093 |
| Net Income (Loss) | $10,483,429 | $(40,910,030) |
| Net Income (Loss) to Common Shareholders | $8,950,973 | $(41,400,758) |
| EPS (Basic) | $0.04 | $(0.31) |
| Research & Development Expenses | $11,911,626 | $6,011,750 |
| General & Administrative Expenses | $6,285,810 | $5,671,595 |
| Cash and Cash Equivalents (End of Period) | $26,568,243 | $33,567,516 |
| Working Capital | $25,799,304 | $34,339,772 |
| Total Assets | $37,804,985 | $46,027,598 |
| Total Liabilities | $9,950,220 | $37,186,954 |
| Stockholders' Equity | $27,854,765 | $8,840,644 |
Note: The 2010 net income is primarily driven by a non-cash gain of $28.8 million on derivative instruments (warrants), not operational profitability.
Material Changes vs. Prior Period
- Derivative Gains/Losses: The most significant change was a swing from a $28.5 million loss on derivative instruments in 2009 to a $28.8 million gain in 2010. This volatility is due to changes in the fair value of warrants and convertible debt based on stock price fluctuations.
- R&D Expenses: Increased by approximately $5.9 million (98%) year-over-year, driven by preparations for the Multikine Phase III clinical trial, including inventory buildup and facility costs.
- Liabilities: Total liabilities decreased significantly from $37.2 million to $9.9 million, largely due to the revaluation and exercise of derivative liabilities (warrants) and the repayment/conversion of Series K convertible debt.
- Cash Position: Cash decreased by approximately $7 million, reflecting operating cash outflows of $12.8 million, partially offset by $6.3 million in financing proceeds from warrant exercises.
Guidance, Outlook, Risks, and Contingencies
- Phase III Trial: CEL-SCI is preparing to launch a global Phase III trial for Multikine in head and neck cancer. The estimated net cost to CEL-SCI is $25–$26 million. Partners (Teva, Orient Europharma) are expected to fund portions of the trial.
- Liquidity Needs: Management states that while current capital allows for patient enrollment, additional funding will be required to complete the Phase III trial and commercialize Multikine. This may come from equity/debt financing or partnerships.
- Legal Contingency: A lawsuit filed by Iroquois Master Fund Ltd. in October 2009 seeks $120 million in damages and additional shares/warrants related to the conversion price of Series K notes. CEL-SCI believes the claims are without merit and has filed for dismissal. If Iroquois prevails, CEL-SCI may be required to issue approximately 1.2 million additional shares and 9.6 million warrants.
- Regulatory Risks: No products are approved. Success depends on FDA and foreign regulatory approvals, which are costly, time-consuming, and uncertain. The H1N1 trial enrollment was hindered by the disappearance of the disease.
- Manufacturing Lease: The company leases a 73,000 sq. ft. facility with annual rent of ~$1.67 million, escalating 3% annually. The lease requires maintaining specific cash levels; failure to do so could trigger default.
Investor Verification Checklist
- Derivative Accounting: Verify the valuation models and assumptions used for the $28.8 million gain on derivative instruments, as this is the primary driver of the reported net income.
- Cash Burn Rate: Assess the runway of the $26.6 million cash balance against the $25–$26 million estimated cost of the Phase III trial and ongoing operating expenses.
- Legal Exposure: Monitor the status of the Iroquois Master Fund lawsuit, as an adverse ruling could result in significant dilution and financial liability.
- Phase III Timeline: Confirm the actual start date and enrollment progress of the Multikine Phase III trial, as delays could necessitate further capital raises.
- Stock Dilution: Review the number of outstanding warrants and options (approx. 83 million shares potentially issuable) and the impact of the "at-the-market" sales agreement with McNicoll Lewis & Vlak LLC.